Pfizer (PFE) Phase 3 study; sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel
Importance
Level 1
#PFIZER INC#PFE.US#IMPORTANT#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES